Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BROOMFIELD, CO, May 16, 2013 (GLOBE NEWSWIRE) -- Colibri Heart Valve, LLC, a privately held medical device company, today announced that Dr. Pedro Ureña will present six month follow-up results from the first-in-human implantation of the Company's proprietary transcatheter aortic heart valve. The Colibri transcatheter aortic valve implantation (TAVI) system (US Patent 8,361,144) is the world's first and only low profile, 14 French pre-mounted, pre-crimped, and pre-packaged, ready-for-use TAVI system. In addition to Dr. Ureña's presentation, the Colibri TAVI system will be highlighted during a panel focused on emerging technologies. These presentations are taking place at EuroPCR 2013, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions taking place May 21-24 in Paris, France.
Help employers find you! Check out all the jobs and post your resume.
BROOMFIELD, CO, May 16, 2013 (GLOBE NEWSWIRE) -- Colibri Heart Valve, LLC, a privately held medical device company, today announced that Dr. Pedro Ureña will present six month follow-up results from the first-in-human implantation of the Company's proprietary transcatheter aortic heart valve. The Colibri transcatheter aortic valve implantation (TAVI) system (US Patent 8,361,144) is the world's first and only low profile, 14 French pre-mounted, pre-crimped, and pre-packaged, ready-for-use TAVI system. In addition to Dr. Ureña's presentation, the Colibri TAVI system will be highlighted during a panel focused on emerging technologies. These presentations are taking place at EuroPCR 2013, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions taking place May 21-24 in Paris, France.
Help employers find you! Check out all the jobs and post your resume.
